HT
APLS

HAP Trading’s Apellis Pharmaceuticals APLS Stock Holding History

HAP Trading’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-126,300
Closed -$132K – 2511
2021
Q3 		$132K Buy
+126,300
New +$7.1M ﹤0.01% 1173

Other funds holding APLS

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

HAP Trading's APLS Position: Q3 2025 in Review

HAP Trading increased its Apellis Pharmaceuticals (APLS) stake by 38% in Q3 2025, buying an estimated $159K and bringing the position to 24,763 shares worth $560K. The position accounts for 0.04% of the portfolio, ranked #246.

HAP Trading first reported a position in APLS in Q2 2024 and has held it in 3 quarters since. The position peaked at $2.49M in Q2 2024. 273 funds tracked by Wall St. Rank hold APLS as of Q3 2025.

  • HAP Trading held 24,763 shares of Apellis Pharmaceuticals worth $560K as of Q3 2025.
  • HAP Trading bought 6,826 Apellis Pharmaceuticals shares in Q3 2025, an estimated $159K.
  • Apellis Pharmaceuticals made up 0.04% of HAP Trading's portfolio in Q3 2025, its #246 holding.
  • HAP Trading first reported a position in Apellis Pharmaceuticals in Q2 2024 and has held it in 3 quarters since.
  • HAP Trading's Apellis Pharmaceuticals position peaked at $2.49M in Q2 2024.
  • 273 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q3 2025.

Based on HAP Trading's 13F filing for Q3 2025, filed 12 Nov 2025.